To date, the notion of inoculating people against drug use is a symbolic one – the idea being that anything from positive peer pressure to self esteem can render people resistant to the lure of drugs. Read More
With published data in hand and preclinical studies underway, Rose Pharmaceuticals is raising money to advance GsMTx4, a nontoxic peptide from spider venom intended to slow muscle degradation in Duchenne's muscular dystrophy. Read More
• Amira Pharmaceuticals Inc., of San Diego, said findings published in the Journal of Pharmacology and Experimental Therapeutics described the biologic effects and characterization of AM095, a lysophosphatidic acid receptor 1 antagonist in in vitro and in vivo models of fibrotic disease. Read More
If imitation is the highest form of praise, it appears that a growing list of companies think very highly of rituximab – and its multi-billion-dollar world market. Read More
Tetralogic Pharmaceuticals Corp., of Malvern, Pa., is wasting no time putting its series C financing to work. The company closed a second and final tranche of $23 million, out of a total $37 million, and has already dosed its first cohort in a Phase Ib/IIa open-label, non-randomized, dose-escalation safety and tolerability study of TL32711 for advanced or metastatic solid tumors. Read More
• Opexa Therapeutics Inc., of The Woodlands, Texas, said it completed FDA meetings to review its optimized manufacturing process for multiple sclerosis vaccine Tovaxin and to discuss a pivotal Phase III trial plan. The drug failed its Phase IIb trial, but a subgroup of patients who were treatment-naïve except for steroids demonstrated a significantly reduced annualized relapse rate and will form the basis for the Phase III study. Opexa's shares (NASDAQ:OPXA) jumped 84cents, or 54 percent, to close at $2.40 on Wednesday. Read More
